Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets Rapidly Expanding and Aging Populations Combined with Earlier Stages at Diagnosis are Driving the Increase in Drug-Treatable Breast Cancer Patient Populations, According to a New Report from Decision Resources
BURLINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with increased awareness and investment in national breast cancer screening programs, the stage at diagnosis of breast cancer in the key Latin American markets is set to shift dramatically over the next 20 years. According to findings from the Strategic Insights report The Impact of Economic Growth on Patient Populations: Breast Cancer Populations in Latin America, the drug-treatable breast cancer patient population will also increase, driven by a rapidly expanding and aging population and earlier stages at diagnosis. Specifically, the adjuvant and neoadjuvant drug-treatable population will increase by 51 percent and the first-line drug-treatable population will increase by 21 percent over the next 10 years.
The findings also reveal that in the adjuvant and neoadjuvant setting in Brazil and Mexico, with HR+ and HER2-overexpressing tumors present in 70 percent and 22 percent of Latin American breast cancer cases, respectively, the growth in hormone therapy and HER2-targeted agents is expected to increase by 51 percent over the next 10 years.
"The risk of breast cancer will increase in Brazil and Mexico as they become more affluent and adopt more-Westernized lifestyles—a key indicator of breast cancer risk," said Decision Resources Senior Epidemiologist Alison Isherwood, Ph.D. "The increasing population, increasing risk of breast cancer and shifting to earlier stages at diagnosis are all driving the increase in the drug-treatable breast cancer populations, so marketers of breast cancer drugs will find significant opportunity in this region."
Countries included in the analysis are Argentina, Brazil, Chile, Colombia, Mexico and Venezuela.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources